Lakefront Biotherapeutics
Lakefront Biotherapeutics, formerly Galapagos, is a Mechelen, Belgium-based clinical-stage biotechnology company founded in 1999 as a joint venture between Crucell and Tibotec. It develops medicines for serious autoimmune diseases, with an immunology pipeline anchored by the investigational BCMAxCD3 T-cell engager gamgertamig.
Key facts
| Legal Name | Galapagos NV |
|---|---|
| Company Operating Status | Active |
| Full Address | Aeschengraben 20 4051 Basel Switzerland |
| Stock Symbol | GLPG |
| Ticker Symbol | LKFT |
| Wikidata ID | Q19903276 |
Contact details
Email and phone for Lakefront Biotherapeutics are available to signed-in members of CliffBio.
Sign in to view